Literature DB >> 21872887

A murine xenograft model of spontaneous metastases of human lung adenocarcinoma.

James E Harris1, James Shin, Beverly Lee, Kristen Pelosky, Craig M Hooker, Kirsten Harbom, Alicia Hulbert, Cynthia Zahnow, Stephen C Yang, Stephen Baylin, Cory Brayton, Malcolm V Brock.   

Abstract

BACKGROUND: The flank is commonly used for primary xenografts in mice, but it is rare for these tumors to metastasize. Tail vein injection creates a pattern of metastases, but is artificial. We hypothesized that the liver is a convenient alternative xenograft site and that metastases would gradually proceed spontaneously.
MATERIALS AND METHODS: Using 15 NOD.CB17-Prkdc(scid)/NcrCrl (NOD/SCID) mice, 10,000 A549 cells were xenografted into the liver while a second group of five mice were xenografted in the flank with 100,000 A549 cells as a control. Mice were euthanized and grossly dissected at 7 wk. A third group of seven mice received liver xenografts with A549 and a mouse each week was euthanized for 7 wk and evaluated. The liver, lung, and spleen were examined histologically.
RESULTS: At 7 wk, 15/15 liver xenografted mice had gross primary tumor in the liver. Histologic review confirmed multiple microscopic foci of metastatic disease in all mice (15/15) throughout the lungs, mediastinal nodes, and spleen. The control group had primary tumor in the flank (4/5), but none had histologic evidence of metastases. Serially euthanized liver xenografted mice revealed evidence of a gradual spontaneous metastatic model system with the first histologic findings of micrometastases appearing in the lungs by wk 5, which became wide spread by wk 7. Splenic and mediastinal lymph node metastases developed in wk 6 and 7.
CONCLUSIONS: Liver xenografting of A549 cells into NOD/SCID mice is a reliable way of developing widespread micrometastases. This model allows the study of a gradually developing solid tumor with subsequent metastatic spread.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21872887      PMCID: PMC3298364          DOI: 10.1016/j.jss.2011.06.058

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  13 in total

1.  Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.

Authors:  C J Bruns; W Liu; D W Davis; R M Shaheen; D J McConkey; M R Wilson; C D Bucana; D J Hicklin; L M Ellis
Journal:  Cancer       Date:  2000-08-01       Impact factor: 6.860

2.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

3.  Pancreatic cancer in mice and man: the Penn Workshop 2004.

Authors:  Ralph H Hruban; Anil K Rustgi; Teresa A Brentnall; Margaret A Tempero; Christopher V Wright; David A Tuveson
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

4.  Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma.

Authors:  David A Tuveson; Liqin Zhu; Aarthi Gopinathan; Nicholas A Willis; Leili Kachatrian; Rebecca Grochow; Christopher L Pin; Natalia Y Mitin; Elizabeth J Taparowsky; Phyllis A Gimotty; Ralph H Hruban; Tyler Jacks; Stephen F Konieczny
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

5.  National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers.

Authors:  Edward F Patz; Neil E Caporaso; Steven M Dubinett; Pierre P Massion; Fred R Hirsch; John D Minna; Constantine Gatsonis; Fenghai Duan; Amanda Adams; Charles Apgar; Rosa M Medina; Denise R Aberle
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

Review 6.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

7.  Behavior of intravenously injected malignant lymphoma cells. A morphologic study.

Authors:  K P Dingemans
Journal:  J Natl Cancer Inst       Date:  1973-12       Impact factor: 13.506

8.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors.

Authors:  Andy J Minn; Yibin Kang; Inna Serganova; Gaorav P Gupta; Dilip D Giri; Mikhail Doubrovin; Vladimir Ponomarev; William L Gerald; Ronald Blasberg; Joan Massagué
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

Review 9.  Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium.

Authors:  Alexander Yu Nikitin; Ana Alcaraz; Miriam R Anver; Roderick T Bronson; Robert D Cardiff; Darlene Dixon; Armando E Fraire; Edward W Gabrielson; William T Gunning; Diana C Haines; Matthew H Kaufman; R Ilona Linnoila; Robert R Maronpot; Alan S Rabson; Robert L Reddick; Sabine Rehm; Nora Rozengurt; Hildegard M Schuller; Elena N Shmidt; William D Travis; Jerrold M Ward; Tyler Jacks
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

10.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

Authors:  D J Giard; S A Aaronson; G J Todaro; P Arnstein; J H Kersey; H Dosik; W P Parks
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

View more
  4 in total

1.  Ex vivo four-dimensional lung cancer model mimics metastasis.

Authors:  Dhruva K Mishra; Chad J Creighton; Yiqun Zhang; Fengju Chen; Michael J Thrall; Min P Kim
Journal:  Ann Thorac Surg       Date:  2015-02-18       Impact factor: 4.330

2.  CCR7 promote lymph node metastasis via regulating VEGF-C/D-R3 pathway in lung adenocarcinoma.

Authors:  Jie Yu; Shaolin Tao; Pingping Hu; Ruwen Wang; Chunshu Fang; Yi Xu; Di Qi; Zhuanqin Wei; Jingge Zhang; Qunyou Tan
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

3.  High mobility group box 1 antagonist limits metastatic seeding in the lungs via reduction of cell-cell adhesion.

Authors:  Adi Karsch-Bluman; Benzion Amoyav; Nethanel Friedman; Hila Shoval; Ouri Schwob; Ezra Ella; Ori Wald; Ofra Benny
Journal:  Oncotarget       Date:  2017-05-16

4.  Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.

Authors:  Viviana Volta; Elia Ranzato; Simona Martinotti; Simone Gallo; Maria Veronica Russo; Luciano Mutti; Stefano Biffo; Bruno Burlando
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.